The inclusion criteria for this Tivantinib study included: doctor-diagnosed T2DM, permanent residents of Tianping Community, more than 40 years of age, and no history of smoking, alcoholism or severe chronic cardiopulmonary diseases. We scheduled 6 follow-up visits every 2 weeks from 13 April 2013 to 30 June 2013. The subjects were randomly divided into 4 subgroups and were invited to take part in BP examinations on one day of two weekends at a 2-week interval to capture day-to-day variations in levels of PM and BP. Each examination was conducted at the same time of the same day of week to exclude any circadian rhythms. We used a self-administered questionnaire to collect personal information including name, address, age, sex, education status, income level, blood glucose level, recent history of medication, and activity patterns 3 days before the scheduled body examination. Height and weight were measured at the first follow-up to calculate the body mass index (BMI). This study was approved by the Institutional Review Board of the School of Public Health, Fudan University, and informed consent was provided by each participant.